Innoviva, Inc. (NASDAQ:INVA) Shares Acquired by Bokf Na

Bokf Na lifted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 2.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 28,648 shares of the biotechnology company’s stock after acquiring an additional 641 shares during the period. Bokf Na’s holdings in Innoviva were worth $495,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of INVA. Illinois Municipal Retirement Fund grew its position in Innoviva by 2.8% during the 4th quarter. Illinois Municipal Retirement Fund now owns 29,066 shares of the biotechnology company’s stock worth $504,000 after purchasing an additional 784 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Innoviva by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,274 shares of the biotechnology company’s stock valued at $230,000 after buying an additional 1,241 shares during the last quarter. Avantax Advisory Services Inc. increased its position in shares of Innoviva by 8.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 18,501 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 1,381 shares during the period. Sterling Capital Management LLC raised its stake in Innoviva by 6.8% in the 4th quarter. Sterling Capital Management LLC now owns 22,924 shares of the biotechnology company’s stock worth $398,000 after acquiring an additional 1,452 shares during the last quarter. Finally, Royce & Associates LP raised its stake in Innoviva by 3.0% in the 4th quarter. Royce & Associates LP now owns 59,625 shares of the biotechnology company’s stock worth $1,034,000 after acquiring an additional 1,717 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Price Performance

NASDAQ:INVA opened at $18.56 on Friday. The firm’s fifty day moving average is $17.90 and its two-hundred day moving average is $18.33. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of 26.90 and a beta of 0.35. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.64 and a current ratio of 1.79. Innoviva, Inc. has a one year low of $15.20 and a one year high of $21.28.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $0.25 EPS for the quarter. The firm had revenue of $88.63 million for the quarter. Innoviva had a return on equity of 20.84% and a net margin of 18.31%. Research analysts expect that Innoviva, Inc. will post 0.33 EPS for the current year.

Insiders Place Their Bets

In other Innoviva news, major shareholder Alexander J. Denner sold 1,196,746 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $17.52, for a total value of $20,966,989.92. Following the completion of the transaction, the insider now owns 5,658,705 shares in the company, valued at approximately $99,140,511.60. This represents a 17.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 2.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on INVA shares. Scotiabank initiated coverage on Innoviva in a report on Friday, March 7th. They issued a “sector outperform” rating and a $55.00 price objective on the stock. StockNews.com upgraded shares of Innoviva from a “hold” rating to a “buy” rating in a report on Wednesday, April 30th.

Innoviva Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.